Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?

Authors

  • Kevin B. Kim MD

    Corresponding author
    1. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030

    Search for more papers by this author
    • Fax: (713) 745-1046


  • See referenced original article on pages 586–92, this issue.

Abstract

Bevacizumab and other drugs targeting vascular endothelial growth factor and/or its receptor have shown encouraging clinical outcomes in early-phase studies when they are combined with cytotoxic chemotherapy drugs. The success of bevacizumab or other antiangiogenic drugs in the treatment of patients with advanced melanoma will depend on a better understanding of tumoral neovascularization and its effect on tumor stromal tissues, as well as on selecting patients with appropriate relevant biomarkers to yield improved clinical outcomes.

Ancillary